{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:21:09Z","timestamp":1778570469028,"version":"3.51.4"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,3,8]],"date-time":"2011-03-08T00:00:00Z","timestamp":1299542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>There is little information published comparing peripheral blood stem cells (PBSC) with bone marrow (BM) as the stem cell source in the long\u2010term outcome in recipients of T\u2010cell depleted (TCD) unrelated donor (UD) transplants. We present retrospective outcome data on 306 recipients of myeloablative, human leucocyte antigen\u2010matched UD allografts using pre\u2010transplant <jats:italic>in\u2010vivo<\/jats:italic> Alemtuzumab. Transplants were performed between 2000 and 2007 for chronic myeloid leukaemia in first chronic phase and acute leukaemia in first or second complete remission; 184 patients received BM and 122 PBSC. The median age was 28\u00b79\u2003years (&lt;1\u201358) and the median follow\u2010up was 48\u2003months. Overall survival at 8\u2003years was 53%. The incidence of acute graft\u2010versus\u2010host disease (GvHD) was significantly higher in PBSC (65%) than BM recipients (49%; <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7012). This represented only grade 1 GvHD with no difference in grade II\u2013IV aGvHD (BM 23% PBSC 24%). The incidence of chronic GvHD, either overall (BM 47%, PBSC 49%) or extensive (BM 15%, PBSC 13%) was not increased with PBSC. The incidence of relapse, non\u2010relapse mortality and survival were not significantly different. Whilst accepting the limitations of retrospective analyses, we suggest the increased risk of GvHD in recipients of PBSC in T\u2010replete transplants is offset by <jats:italic>in\u2010vivo<\/jats:italic> Alemtuzumab, and that either stem cell source can be used with good outcomes in this setting.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08615.x","type":"journal-article","created":{"date-parts":[[2011,3,8]],"date-time":"2011-03-08T13:02:48Z","timestamp":1299589368000},"page":"244-252","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Unrelated donor peripheral blood stem cell transplants incorporating pre\u2010transplant <i>in\u2010vivo<\/i> Alemtuzumab are not associated with any increased risk of significant acute or chronic graft\u2010versus\u2010host disease"],"prefix":"10.1111","volume":"153","author":[{"given":"Bronwen E.","family":"Shaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Effie","family":"Liakopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel M.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiren","family":"Kirkland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Alejandro","family":"Madrigal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.2942"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.12.034"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702734"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1071"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02519.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.013920"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.189"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.08.006"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2008.02.008"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70225-6"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70352-3"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.006924"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703778"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.593"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176350951"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1182\/blood.V92.12.4581","article-title":"Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft\u2010versus\u2010host disease and graft rejection","volume":"92","author":"Hale G.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.08.010"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.7.2419"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2008.00997.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.141"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.375"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70031-0"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.05.018"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3629"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/338624"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701037"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175323"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/146532401317070899"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1739"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1000"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.049"},{"key":"e_1_2_8_34_1","first-page":"643","article-title":"Filgrastim\u2010mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3\u2010year results from the EBMT randomized trial","volume":"90","author":"Schmitz N.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024042"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.020"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.12.4705"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66996-6"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08615.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08615.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:43:30Z","timestamp":1697413410000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08615.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,8]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08615.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08615.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,8]]},"assertion":[{"value":"2011-03-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}